U.S. coronavirus vaccine test results bring ‘good news,’ wider trials next: Fauci

Click to play video: 'When will a COVID-19 vaccine be ready?' When will a COVID-19 vaccine be ready?
Researchers are hopeful a COVID-19 vaccine will be ready within 12 months but University of Guelph Viral Immunologist Byram Bridle explains why he thinks that's unrealistic and the risks associated with fast-tracking a vaccine. – Jul 1, 2020

The first COVID-19 vaccine tested in the U.S. revved up people’s immune systems just the way scientists had hoped, researchers reported Tuesday — as the shots are poised to begin key final testing.

“No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press.

Read more: 1st Canadian human trial for coronavirus vaccine is underway. Here’s what that means

The experimental vaccine, developed by Fauci’s colleagues at the National Institutes of Health and Moderna Inc., will start its most important step around July 27: A 30,000-person study to prove if the shots really are strong enough to protect against the coronavirus.

But Tuesday, researchers reported anxiously awaited findings from the first 45 volunteers who rolled up their sleeves back in March. Sure enough, the vaccine provided a hoped-for immune boost.

Story continues below advertisement
Click to play video: 'Coronavirus: Dr. Njoo ‘encouraged’ by start of Canadian COVID-19 vaccine trials, but urges patience' Coronavirus: Dr. Njoo ‘encouraged’ by start of Canadian COVID-19 vaccine trials, but urges patience
Coronavirus: Dr. Njoo ‘encouraged’ by start of Canadian COVID-19 vaccine trials, but urges patience – Jul 14, 2020

Those early volunteers developed what are called neutralizing antibodies in their bloodstream — molecules key to blocking infection — at levels comparable to those found in people who survived COVID-19, the research team reported in the New England Journal of Medicine.

“This is an essential building block that is needed to move forward with the trials that could actually determine whether the vaccine does protect against infection,” said Dr. Lisa Jackson of the Kaiser Permanente Washington Research Institute in Seattle, who led the study.

Read more: Quebec company begins human trials of coronavirus vaccine

There’s no guarantee but the government hopes to have results around the end of the year — record-setting speed for developing a vaccine.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

The vaccine requires two doses, a month apart.

Story continues below advertisement

There were no serious side effects. But more than half the study participants reported flu-like reactions to the shots that aren’t uncommon with other vaccines — fatigue, headache, chills, fever and pain at the injection site. For three participants given the highest dose, those reactions were more severe; that dose isn’t being pursued.

Click to play video: 'VIDO-InterVac shifts focus to hamsters in efforts to create COVID-19 vaccine' VIDO-InterVac shifts focus to hamsters in efforts to create COVID-19 vaccine
VIDO-InterVac shifts focus to hamsters in efforts to create COVID-19 vaccine – Jul 8, 2020

Some of those reactions are similar to coronavirus symptoms but they’re temporary, lasting about a day and occur right after vaccination, researchers noted.

“Small price to pay for protection against COVID,” said Dr. William Schaffner of Vanderbilt University Medical Center, a vaccine expert who wasn’t involved with the study.

He called the early results “a good first step,” and is optimistic that final testing could deliver answers about whether it’s really safe and effective by the beginning of next year.

Story continues below advertisement

“It would be wonderful. But that assumes everything’s working right on schedule,” Schaffner cautioned.

Read more: The race for a vaccine: China leads the way in a potential coronavirus treatment

Moderna’s share price jumped nearly 15 percent in trading after U.S. markets closed. Shares of the company, based in Cambridge, Massachusetts, have nearly quadrupled this year.

Tuesday’s results only included younger adults. The first-step testing later was expanded to include dozens of older adults, the age group most at risk from COVID-19. Those results aren’t public yet but regulators are evaluating them. Fauci said final testing will include older adults, as well as people with chronic health conditions that make them more vulnerable to the virus — and Black and Latino populations likewise affected.

Click to play video: 'Coronavirus: ‘No guarantee’ safe COVID-19 vaccine will be made, Fauci says' Coronavirus: ‘No guarantee’ safe COVID-19 vaccine will be made, Fauci says
Coronavirus: ‘No guarantee’ safe COVID-19 vaccine will be made, Fauci says – Jun 30, 2020

Nearly two dozen possible COVID-19 vaccines are in various stages of testing around the world. Candidates from China and Britain’s Oxford University also are entering final testing stages.

Story continues below advertisement

The 30,000-person study will mark the world’s largest study of a potential COVID-19 vaccine so far. And the NIH-developed shot isn’t the only one set for such massive U.S. testing, crucial to spot rare side effects. The government plans similar large studies of the Oxford candidate and another by Johnson & Johnson; separately, Pfizer Inc. is planning its own huge study.

Already, people can start signing up to volunteer for the different studies.

Read more: Herd immunity won’t save us from the coronavirus pandemic

People think “this is a race for one winner. Me, I’m cheering every one of them on,” said Fauci, who directs NIH’s National Institute of Allergy and Infectious Diseases.

“We need multiple vaccines. We need vaccines for the world, not only for our own country.”

Around the world, governments are investing in stockpiles of hundreds of millions of doses of the different candidates, in hopes of speedily starting inoculations if any are proven to work.

Sponsored content